Concepedia

The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin

Alessandra Mangia, Andrea Arleo, Massimiliano Copetti, Maria Miscio, Valeria Piazzolla, Rosanna Santoro, Maria Maddalena Squillante

Liver International · 2016 · 33 citations · 17 references

DOI

Abstract

This study supports the use of SOF/DCV for 12 weeks in non-cirrhotics or 24 weeks in cirrhotic GT-2 patients who cannot tolerate RBV, including those with decompensated disease.

References

17

Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold

Peter J. Neumann, Joshua T. Cohen, Milton C. Weinstein · New England Journal of Medicine · 2014 · 2.2K citations

, , +23

Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection

Eric Lawitz, Alessandra Mangia, David Wyles et al. · New England Journal of Medicine · 2013 · 1.8K citations

Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

Nezam H. Afdhal, Stefan Zeuzem, Paul Y. Kwo et al. · New England Journal of Medicine · 2014 · 1.7K citations · Full text

Global distribution and prevalence of hepatitis C virus genotypes

Jane P. Messina, Isla Humphreys, Abraham D. Flaxman et al. · Hepatology · 2014 · 1.6K citations · Full text

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

Nezam H. Afdhal, K. Rajender Reddy, David R. Nelson et al. · New England Journal of Medicine · 2014 · 1.3K citations